

# Sleep quality in patients with Parkinson's disease in the Republic of Moldova – preliminary results

*By Lilia Rotaru*

**TYPE OF ARTICLE:** Original Article

## **Sleep quality in patients with Parkinson’s disease in the Republic of Moldova – preliminary results**

Lilia Rotaru<sup>1</sup>, Madalina Cebuc<sup>1,2</sup>, Oxana Grosu<sup>1</sup>, Adrian Lupusor<sup>1,2</sup>, Ion Moldoveanu<sup>1</sup>, Stela Odobescu<sup>1</sup>, Svetlana Lozovanu<sup>2</sup>, Victor Vovc<sup>2</sup>, Ghenadie Carausu<sup>4</sup>, Stanislav Groppa<sup>3</sup>

<sup>1</sup> Research Department, “Diomid Gherman” Institute of Neurology and Neurosurgery, Chisinau, Republic of Moldova

<sup>2</sup> Department of Biophysics and Human Physiology, “Nicolae Testemitanu” State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

<sup>3</sup> Department of Neurology No. 2, “Nicolae Testemitanu” State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

<sup>4</sup> Department of Mental Health, Medical Psychology and Psychotherapy, “Nicolae Testemitanu” State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

**Corresponding author:**

Lilia Rotaru

*E-mail:* [liliarotaru@yahoo.com](mailto:liliarotaru@yahoo.com)

### **ABSTRACT**

**Background and objectives.** The rising prevalence of sleep issues are a consequent societal problem notably impacting individuals with Parkinson’s disease (PD). This study aims to examine the differences in sleep quality between diagnosed patients and their counterparts, while also highlighting its effects on their symptoms and quality of life.

**Materials and methods.** This study enrolled 37 PD subjects. Sleep quality, established via Pittsburgh Sleep Quality Index (PSQI), was compared through a case control approach against 49 control subjects. PD symptomatology assessment was ensured via: Hoehn & Yahr (H&Y); Movement Disorder Society-Unified Parkinson’s disease Rating Scale (MDS-UPDRS I-IV); Non-motor Symptom Scale (NMSS); Beck Depression Inventory (BDI); Montreal Cognitive Assessment (MoCA); Scale for Outcomes in Parkinson’s disease – Psychosocial Functioning (SCOPA-PS); 39-Item Parkinson’s Disease Questionnaire (PDQ-39).

**Results.** Compared to their homologues, PD subjects were prone to worse subjective sleep quality (18.9% vs. 8.2%), sleep efficiency (13.5% vs. 4.1%), diurnal functionality (27% vs. 12.2%), sleep related breathing disorders (62.2% vs. 46.9%). The global PSQI positively correlates to H&Y staging ( $r_p=0.443$ ,  $p=0.008$ ), UPDRS-III ( $r_p=0.369$ ,  $p=0.029$ ), UPDRS-IV ( $r_p=0.412$ ,  $p=0.011$ ). PD subjects with PSQI>5 registered higher UPDRS-III ( $p=0.091$ ), BDI ( $p=0.928$ ), SCOPA-PS ( $p=0.051$ ). PSQI5 correlates to PDQ-39

( $r_p=0.423$ ,  $p=0.010$ ) and SCOPA-PS ( $r_p= 0.462$ ,  $p=0.004$ ).

**Conclusions.** The study proved a clear correlation between altered sleep patterns and the clinical presentation of PD delineating worsening of motor along to non-motor symptoms. In addition, the quality of life along to the psycho-social functioning of PD subjects is at risk in those manifesting sleep disturbances. Correspondingly, great interest must reside in the establishment of prophylactic measures.

11

**Keywords:** Parkinson’s disease, Sleep quality, Motor symptoms, Non-motor symptoms.

46

#### Abbreviations:

BDI – Beck Depression Inventory

H&Y – Hoehn & Yahr

17

MDS-UPDRS – Movement Disorder Society-Unified Parkinson’s disease Rating Scale

MoCA – Montreal Cognitive Assessment

NMSS – Non-motor Symptom Scale

PD – Parkinson’s disease

24

PDQ-39 – 39-Item Parkinson’s Disease Questionnaire

SCOPA– PS – Scale for Outcomes in Parkinson’s disease – Psychosocial Functioning

18

## INTRODUCTION

Parkinson’s disease (PD) is the second most common neurodegenerative disorder [1] characterized by the loss of dopaminergic neurons in the substantia nigra compacta. It has acquired significant interest due to the aging population, particularly in developed regions. Previously thought to only manifest as extrapyramidal motor dysfunction, it is now understood to be a more complex condition involving a wide range of non-motor aspects such as sleep, neuropsychiatric, autonomic and sensory disorders.

The subject of sleep disorders has acquired increased interest as per the social and economic burden they impose. Several large-scale studies showed how deeply the public health care systems have been affected worldwide by this issue[2,3]; most commonly associated to the specifics of modern lifestyles, social features of the environments we live in and advances in technology subjecting us to more screen exposure time [4,5]. Additionally, in the time-frame of the eventful past years, crisis situations (the COVID-19 pandemic, war and political instability, natural disaster) showed to drastically alter sleep in the general population [5,6].

Recent studies in molecular research have discovered connections between the development and advancement of synucleinopathies like PD, and sleep patterns specifically by creating a favorable milieu for the built up of pathologic proteins and neuroinflammation. Consequently, disrupted sleep schedules increase the generation of misfolded proteins, leading to their buildup in the interstitial space and in the glymphatic system which encourages aggregate formation [7–9]. The presence of protein waste triggers

reactive gliosis and an inflammatory reaction that is amplified under conditions with decreased antioxidant defenses due to the dampened melatonin production [8,10].

From a clinical perspective, PD prodrome is strongly linked to changes in brain structures resulting in REM sleep behavior disorder (RBD) that could also be perceived as an early indicator of synucleinopathy. Studies show that 44% of patients converting to Parkinson's disease after a mean follow-up of  $4.75 \pm 2.43$  years; and 80 - 90% of them developing a neurodegenerative disorder 14 years later [11–14]. As the condition progresses, sleep regulatory structure's involvement accentuates leading to further alterations in sleep patterns contributing to the advancement of neurodegeneration.

The aforementioned advancements in understanding the underlying mechanisms sleep disruption are associated to PD, lead to a duplication of researches in the world evaluating the weight they produce on the clinical presentation of the condition. However, this domain is relatively new in Republic of Moldova where sleep medicine per se is a new field of interest. Thus, through this preliminary study we aim to identify how variations in sleep quality parameters reflects upon the symptomatology of PD in Republic of Moldova, by identifying the impact on the motor and non-motor symptoms along to the degree in alteration of the quality of life.

## MATERIALS AND METHODS

### *Clinical evaluation*

An exhaustive evaluation of the subjects was performed encompassing demographic data, disease staging (Hoehn & Yahr scale), Levodopa Equivalent Daily Dosage (LEDD), along to clinical assessment. Upon the granted permission of use of the International Parkinson's Disease and Movement Disorder Society, several scales were employed to evaluate symptoms:

- The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) parts I-IV for the evaluation of the degree of motor dysfunction;
- The Non-Motor Symptom Scale (NMSS) for the assessment of the severity and frequency of the non-motor symptoms (cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastrointestinal tract, urinary, sexual function, miscellaneous);
- The Scale for Outcomes in Parkinson's disease – Psychosocial Functioning (SCOPA – PS) in order to illustrate the overall psychosocial functioning of the individual.

Complementary questionnaires used to evaluate the degree of depression and cognition were: the Beck Depression Index (BDI) and the Montreal Cognitive Assessment (MoCA) analyzing (visuospatial/executive skills, memory, attention, language, abstraction, memory and orientation). The overall quality of life during the past month in PD subjects was evaluated via the 39-Item Parkinson's Disease Questionnaire (PDQ-39) depicting the degree of impairment of: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication and bodily discomfort.

### *Sample characteristics*

This study presents a cross-sectional analysis of sleep characteristics in Parkinson's disease patients conducted at the "Diomid Gherman" Institute of Neurology and Neurosurgery in Chisinau, Republic of Moldova, from 2020 to 2023.

The study involves a preliminary assessment of a smaller group comprising 37 PD patients (men: 40.5% (n=15); women: 59.5% (n=22)) with an average age of  $59.97 \pm 8.50$  years, selected from a larger pool of individuals who did not meet the eligibility criteria requiring a confirmed diagnosis of Parkinson's disease and excluding those with notable neurological and systemic comorbidities, as well as individuals with Parkinson plus syndromes or other neurodegenerative conditions.

Complementary, a control sample of 49 subjects (44.9% males (n=22) and 55.1% females (n=27)) with an average age of  $61.33 \pm 15.28$  years was selected to compare the sleep quality differences between PD and non-PD individuals using a case-control approach. Inclusion criteria required the absence of any parkinsonian syndromes or major neurological disorders.

### *Sleep quality evaluation*

The Pittsburgh Sleep Quality Index (PSQI) was used - a self-administered questionnaire portraying the quality of sleep throughout the past month by depicting the degree of disruption of seven components: subjective sleep quality (PSQI1), sleep latency (PSQI 2), sleep duration (PSQI 3), habitual sleep efficiency (PSQI 4), sleep disturbances (PSQI5), use of sleep medication (PSQI 6), daytime dysfunction (PSQI 7). Therefore, to assess the impact of sleep quality on both motor and non-motor symptoms, two sub-groups were created for analysis based on their Pittsburgh Sleep Quality Index scores: PSQI <5 points – representing good sleepers (n=17), and PSQI >5 points – indicating poor sleepers (n=20).

### *Statistical evaluation*

The statistical assessment of the collected data was ensured via Epi Info™, several analysis methods being used in conformity to the data types. Descriptive statistics were employed to contour the traits of the samples including demographic specifics, along to variances in obtained scores and responses to the questionnaires. Inferential statistics were ensured by: the independent t-student test for the interpretation of scores (PSQI, SCOPA-PS, BDI, MoCA, NMSS, MDS-UPDRS I-IV, PDQ-39); and the chi-square test for all of the categorial values. The association of various sleep components to the evaluated clinical traits of Parkinson's disease was established through the Pearson correlation test. The first step into the analysis was the evaluation of differences in sleep quality among PD and control subjects, with subsequent identification of the types of sleep dysfunctions prevailing each group. The second step was the assessment of correlations between sleep quality parameters and PD symptomatology, followed by a secondary analysis of those symptoms in perspective to the preserved or altered sleep quality.

## RESULTS

### *Cohort general characteristics*

The study included 86 subjects divided into the PD and control sample characterized by approximately similar mean ages ( $59.97 \pm 8.50$  vs.  $61.33 \pm 15.28$ ,  $p=0.628$ ) and gender distributions (40.5% males and 59.5% females in the PD group, 44.9% males and 55.1% females in the control group).

The overall functional disability in subjects with PD corresponded to Hoehn and Yahr stage II-III, with a mean score of  $2.071(\pm 0.423)$ . Mild motor impairment was observed based on the MDS-UPDRS III score ( $15.60 \pm 9.876$ ) whilst subjects administered a baseline antiparkinsonian treatment, with an average LEDD (levodopa equivalent daily dose) of  $641.946 (\pm 327.918)$  (Table 1).

### *Sleep quality in Parkinson's disease vs. control*

The comparative analysis between the samples showed accentuated alterations in sleep quality in the control subjects ( $6.757, \pm 4.212$  vs.  $8.143, \pm 3.403$ ,  $p < 0.001$ ) (Table 4). A majority of them (63.3%) affirmed using sleep medication during the previous month, in addition to have a history of night shift (36.7%). In subjects diagnosed with Parkinson's disease several sleep disturbances prevailed such as diminished subjective sleep quality (18.9% vs. 8.2%), sleep efficiency (13.5% vs. 4.1%), diurnal functionality (27% vs. 12.2%) and more pronounced sleep related breathing disorders (62.2% vs. 46.9%) (Table 3).

### *Sleep quality impact on motor and non-motor symptoms in Parkinson's disease*

The analysis provided several findings regarding the relationship between sleep quality and the clinical manifestations in Parkinson's disease. The mean PSQI score in the studied subjects differ greatly among the samples ( $3.235, \pm 1.091$  vs.  $9.750, \pm 3.477$ ,  $p < 0.001$ ) (Table 4). Longer sleep duration was registered in the sub-group with preserved sleep quality ( $6.985, \pm 0.731$  vs.  $5.731, \pm 1.209$ ,  $p=0.001$ ) along to shorter sleep latency ( $19.352, \pm 41.845$  vs.  $46.275, \pm 51.936$ ,  $p=0.090$ ) (Table 4).

Data showed higher LEDD in subjects with  $PSQI < 5$  ( $672.059, \pm 344.750$  vs.  $616.35, \pm 319.616$ ,  $p=0.616$ ), suggesting that patients with better sleep quality were receiving higher doses of levodopa equivalent medication. Furthermore, there was a moderate positive association between disease staging evaluated by Hoehn & Yahr and the global PSQI score ( $r_p = 0.443$ ,  $p=0.008$ ).

The Pearson correlation test also illustrated moderate correlations between the sleep quality and motor symptoms such as: UPDRS-III ( $r_p = 0.369$ ,  $p=0.029$ ) and UPDRS-IV ( $r_p = 0.412$ ,  $p=0.011$ ); which is sustained by similar results regarding multiple of the constituents of PSQI. The overall UPDRS scores were higher in subjects with altered sleep (UPDRSIII –  $32.76, \pm 13.890$  vs.  $39.72, \pm 8.917$ ,  $p=0.091$ ). Regarding the non-motor symptoms, strong and moderate correlations were seen among NMSS and several components of sleep: PSQI ( $r_p = 0.518$ ,  $p=0.001$ ) or PSQI5 ( $r_p = 0.339$ ,  $p=0.047$ ). Both samples noted mild depressive symptoms, with a greater degree observed in those with  $PSQI > 5$  ( $11.76, \pm 9.477$  vs.  $12.05, \pm 9.473$ ,

p=0.928) (Table 2,4).

The degree of life quality in subjects with Parkinson's disease presented a modest link without statistical significance (PDQ-39 vs. global PSQI:  $r_p=0.287$ ,  $p=0.089$ ), however a moderate association could be observed with one of the sleep components (PDQ-39 vs. PSQI 5  $r_p=0.423$ ,  $p=0.010$ ). From a psycho-social perspective, a correlation was found with sleep latency and the presence of sleep disturbances (SCOPA-PS vs: PSQI2 ( $r_p=0.443$ ,  $p=0.006$ ); PSQI5 ( $r_p=0.462$ ,  $p=0.004$ )). In addition, subjects with higher PSQI had worst SCOPA-PS scores ( $6.00, \pm 5.136$ , vs.  $10.10, \pm 7.166$ ,  $p=0.051$ ) (Table 2, 4).

## DISCUSSION

### *Sleep quality in Parkinson's disease subjects compared to general population*

The characteristics of sleep-wake cycles bear great importance in the various stages of Parkinson's or any neurodegenerative disorders' evolution. Their disruption was shown to create the adequate milieu for the instigation and progression of the pathology. In addition, as the neurodegenerative modifications advance, so does the involvement of brain structures ensuring the homeostasis and regulation of sleep patterns [15,16].

Hence, the study conducted was built upon the hypothesis that the sleep quality would be more altered in PD subjects compared to control, fact disproved in our analysis since the PSQI scores were fairly higher in the latter sample ( $6.757, \pm 4.212$  vs.  $8.143, \pm 3.403$ ,  $p<0.001$ ). This outcome contradicts to that of researches with larger samples and meta-analyses that distinguish up to 63% of patients presenting sleep disorders, making those the most common non-motor symptoms registered encompassing a wide array of pathological entities such as: insomnia, excessive day-time sleepiness, REM (rapid eye movement) sleep behavior disorder and disrupted breathing patterns in sleep [15,17]. This latter element proved to also prevail in the analyzed PD individuals compared to control (62.2%). The overall of the PSQI components evaluated in this research noted greater degree of deterioration in control subjects. However, from a purely descriptive stand point, was observed that the duration of sleep in PD subjects was lower ( $6.318, \pm 1.182$  vs.  $9.921, \pm 1.403$ ,  $p=0.623$ ). This type of reduction is commonly seen as an individual ages, but was proven to be more accentuated in those with Parkinson's, fact supported by polysomnographic studies that also point out greater sleep latencies, fragmentation and reduction of the overall efficiency [16–18].

Limitations in our study and discrepancies between the results obtained and other similar studies can be attributed to the small sample sizes, along to several other elements that can impact one's steadiness of sleep-wake cycles. For instance, most of control subjects stated to have worked nightshifts compared to subjects with PD (36.7% vs. 13.5% ( $\chi^2=5.802$ ,  $df=1$ ,  $p=0.016$ )). The results thus portray a rather controversial action of disrupted sleep patterns and circadian clocks on the genesis of PD – several studies showing no association [19,20], in contrast to others underlined an impact upon the development of the disease [21,22]. Complementary, a deeper research on the demographic peculiarities of the control group would be needed to establish if underlying neurological or somatic conditions were not negatively impacting sleep patterns in those subjects. In addition, further investigation of circadian and environmental

sleep-wake cycle modifiers should be evaluated as per their ability to shape the entire sleep pattern [9,23–25].

### **Motor symptoms in Parkinson's disease based on the quality of sleep**

When considering Parkinson's disease, the primary features that come to mind are the distinct motor symptoms such as bradykinesia, rest tremor, rigidity, and hypokinesia. This study made several observations regarding their correlation with sleep quality.

Hence, the analysis of the motor function of the studied sample proved a positive moderate correlation between UPDRS III and PSQI scores ( $r_p=0.369$ ,  $p=0.029$ ). This result is supported by data obtained in a similarly structured study (PSQI vs. UPDRSII-III,  $p<0.001$ ) [26]. However, the deterioration/improvement of which of the variables is of main interest is unprecise. Researches on the subjects point out the bidirectionality among those two entities - increased motor deficits are linked to higher rates of a variety of sleep disorders and vice-versa. Subsequently, correlations were found between the various elements defining insomnia based on the International Classification of Sleep Disorders (ICSD) -3 – notably: sleep initiation, maintenance or early awakenings; and oscillations in motor function in PD subjects [27–29]. Other researches pointed out the association between restless limb syndrome and higher UPDRS III scores, also reflected in those with advanced Hoehn & Yahr stages [30,31]. A possible explanation linking those two entities would be the progressive implication of dopaminergic structures accounting for the pathophysiology of both conditions. Multiple studies concentrate on parasomnias in Parkinson's, with particular accent on REM sleep behavior disorder (RBD), proving its prodromal nature and utility a tool in assessing one's susceptibility to develop the disease up to 10 years before its onset [27,32–34]. Based on Braak's theory, this phenomenon could be explained by the early involvement of sleep regulatory structures in the pons and medulla responsible for inhibition of movement enactment during sleep before the synucleopathy spreads to mesencephalic structures. A non-negligible element is that the condition persists after photoconversion of PD and can further more accentuate movement deficits.

Other motor nuisances in PD that compromise one's sleep efficiency is impaired bed mobility. Patients suffer from reduced capacity at executing nocturnal movements such as turning or changing posture in bed, the following being associated to more advanced disease stages [35]. Several longitudinal researches contoured their prodromal nature for those disturbances can manifest years before the onset of PD [32,35]. In addition, discomfort and pain produced by the impairment furthermore accentuates excessive day-time sleepiness and the degradation of quality of life [35].

### **Non-motor symptoms in Parkinson's disease based on the quality of sleep**

Non-motor symptom scale, which sums up the repercussions of a wide array of psycho-somatic clinical manifestations found in PD, was particularly useful in evaluating the weight those have on Parkinson's disease proving the positive correlations with sleep latency ( $p=0.001$ ) and sleep disturbances ( $p=0.047$ ). In



addition, subjects with altered sleep had poorer NMSS scores ( $p=0.529$ ), this result being supported by a similar study conducted on a larger samples ( $p<0.001$ )[26].

The analysis showed only a slight difference between cognitive functions among the sub-groups ( $p=0.798$ ). A study on people at risk in developing Parkinson's showed more accentuate cognitive impairment in individuals diagnosed with RBD via polysomnography than the rest of the sample ( $p<0.001$ )[36]. Complementary, the assessment of the depression degree in those with altered sleep patterns established worse BDI scores ( $p=0.981$ ). Although, the association obtained is inconclusive, other researchers found that PD subjects presenting sleep disruptions such as insomnia, EDS or limb restlessness syndrome were more depressed and anxious than control [15].

All of those results support the idea that chronic sleep disorders enhance neurodegenerative modifications affecting various brain areas involved in regulation of somatic along to cognitive-behavioral functions. The accumulation of modified proteins, especially alpha-synucleins, is enhanced in sleep deprivation by compromising their elimination pathways: the glymphatic systems or endo-/phagocytosis. In addition, they contribute to microgliosis, accumulation of reactive species of oxygen and reduction in protective mechanisms [9].

25

### *Quality of life in Parkinson's disease based on quality of sleep*

Health related quality of life in PD subjects with increased PSQI scores was diminished, presenting higher PDQ-39 scores in contrast to their counterparts ( $48.82, \pm 28.712$  vs.  $59.68, \pm 20.745$ ,  $p = 0.170$ ). Although the results obtained lack statistical significance, a similar study sustain this statement: a research made in between 2011-2013 at the University of Miami Movement Disorder Clinic on 66 individuals with mild to moderate PD showed those diagnosed with insomnia were more affected in their day-to-day life by the disease ( $26.7, \pm 15.4$  vs.  $176, \pm 11.1$ ,  $p<0.001$ )[37]. The evaluation of psycho-social functioning of patients with Parkinson's disease noted the presence of a correlation with the presence of sleep disturbances ( $p=0.004$ ) and greater alterations were found in those with high PSQI ( $p=0.051$ ).

Correspondingly, as the epidemiological data portray, the increase in life expectancy extends the YLDs of those patients causing great burden upon the societies. As countries develop, in the context of this study – those in Eastern European regions such as Republic of Moldova, the need of prophylactic strategies is required. Thus, improving sleep quality in PD and non-PD population represents an effective and cost-efficient preventive measure that needs to be encompassed into a national wide program.

### CONCLUSION

One of the main purposes of this research was to establish how sleep quality varies in patients diagnosed with Parkinson's disease compared to their equals. Based on the gathered results, PD subjects, despite of a more accentuated reduction in sleep duration – characteristic to neurodegenerative processes; had less altered sleep patterns. The result contradicts those of previous studies, but further analysis of modifying factors

could shed light on this discrepancy. However, subjective sleep quality (18.9%), sleep efficiency (13.5%), diurnal functionality (27%) and sleep related breathing disorders (62.2%) prevailed in diagnosed individuals.

Subsequent analysis of symptoms in PD, showed positive dynamics when exposed to steady sleep patterns, correlations being noticed regarding the motor and non-motor dysfunctions. Thus, disorders such as insomnia, RLS, RBS favor the ongoing neurodegenerative modifications related to the pathophysiology of PD whilst altering various brain structures responsible for the wide array of clinical manifestations.

Finally, the research objectified, in concordance to similar studies, the marked decrease in life quality in those diagnosed along to altered psycho-social functioning. Such information shall raise alarm in the context of an ageing population and increase in years lived with the disease, especially for the socio-economic burden it imposes on the health care systems especially in developing countries such as Republic of Moldova. Correspondingly, measures of prophylaxis should be emphasized at younger ages in the frame of the prodromal debut of PD and should be continued even after photoconversion to slow the progression and severity of symptoms.

**Conflict of interest:** The authors certify to <sup>15</sup> not have any financial or personal relationships that might bias the content of this work.

#### **Author's contributions:**

The following individual contributions to this research and article were made:

- Conceptualization: L. Rotaru, M. Cebuc, A. Lupușor.;
- Methodology: L. Rotaru, M. Cebuc, A. Lupușor, O. Grosu;
- Software: O. Grosu, M. Cebuc;
- Validation : L. Rotaru, M. Cebuc, A. Lupușor, O. Grosu;
- Formal analysis: L. Rotaru, O. Grosu, M. Cebuc;
- Investigation: L. Rotaru, M. Cebuc, A. Lupușor.;
- Resources: I. Moldoveanu, S. Odobescu, L. Rotaru, A. Lupușor, S. Lozovanu ;
- Data curation: L. Rotaru, M. Cebuc, O. Grosu, A. Lupușor;
- <sup>29</sup> Writing—original draft preparation: M. Cebuc;
- Writing—review and editing: O. Grosu, M. Cebuc, L. Rotaru, A. Lupușor ;
- Visualization: L. Rotaru, S. Groppa, V. Vovc, I. Moldoveanu, S. Odobescu, S. Lozovanu, Gh.Carausu
- Supervision: L. Rotaru, S. Groppa, V. Vovc, I. Moldoveanu, S. Odobescu, Gh.Carausu;
- Project administration: L. Rotaru;
- <sup>22</sup> Funding acquisition: L. Rotaru, S. Groppa, V. Vovc.

All authors have read and agreed to the published version of the manuscript.

**Acknowledgements:** The research took part of the post-doctoral program 23.00208.8007.01/PD II.

## REFERENCES

1. Deuschl G, Beghi E, Fazekas F, Varga T, Christoforidi KA, Sipido E, et al. The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. *Lancet Public Heal.* 2020;5:e551–67. doi: 10.1016/S2468-2667(20)30190-0
2. Chattu VK, Spence DW, Bahammam AS, Pandi-perumal SR. Insufficient Sleep Syndrome : Is it time to classify it as a major noncommunicable disease? *Sleep* 2018;11:56–64. doi: 10.5935/1984-0063.20180013
3. Hafner M, Troxel WM, Stepanek M, Taylor J VSC. Why Sleep Matters: The Macroeconomic Cost of Insufficient Sleep. *Sleep.* 2017;40:A297. doi: 10.1093/sleepj/zsx050.802
4. Johnson DA, Billings ME, Hale L. Environmental Determinants of Insufficient Sleep and Sleep Disorders : Implications for Population Health. *Curr Epidemiol Rep.* 2018;5:61–9. doi: 10.1007/s40471-018-0139-y%0AENVIRONMENTAL
5. Chami HA, Bechnak A, Isma H, Talih F, Nasreddine L, Nasrallah M, et al. Sleepless in Beirut : Sleep Difficulties in an Urban Environment With Chronic Psychosocial Stress. *Sleep Med.* 2019;15:603–14. doi: 10.5664/jcsm.7724
6. Simonelli G, Petit D, Pizzamiglio J, Michaud X, Denise M, Morin CM, et al. Sleep in times of crises : A scoping review in the early days of the COVID-19 crisis. *Sleep Med Rev.* 2021;60. doi:: 10.1016/j.smrv.2021.101545
7. Cullell N, Cárcel-Márquez J, Gallego-Fábrega C, Muiño E, Llucià-Carol L, Lledós M, et al. Sleep/wake cycle alterations as a cause of neurodegenerative diseases: A Mendelian randomization study. *Neurobiol Aging.* 2021;106:320.e1-320.e12. doi: 10.1016/j.neurobiolaging.2021.05.008
8. Lecours C, Bordeleau M, Cantin L, Parent M, Paolo T Di, Tremblay M-ève, et al. Microglial Implication in Parkinson ' s Disease : Loss of Beneficial Physiological Roles ¶Gain of Inflammatory Functions ? *Front Cell Neurosci.* 2018;12:1–8. doi: 10.3389/fncel.2018.00282
9. Lananna B V., Musiek ES. The wrinkling of time: Aging, inflammation, oxidative stress, and the circadian clock in neurodegeneration. *Neurobiol Dis.* 2020;139. doi: 10.1016/j.nbd.2020.104832 Received
10. Lauretti E, Pratic D. Circadian clock disruption and neuroinflammation in Parkinson ' s disease : a new perspective [Internet]. *Genet. Neurol. Behav. Diet Park. Dis. Neurosci. Park.* Vol. 2. Elsevier; 2020. doi: 10.1016/B978-0-12-815950-7.00022-9
11. Tolosa E, Molinuevo L, Iranzo A, Ferna A, Llado A, Valldeoriola F, et al. Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder : Study n174 Patients. *PLoS One.* 2014;9:e89741. doi:: 10.1016/j.nbd.2020.104832 Received
12. Galbiati A, Verga L, Giora E, Zucconi M, Ferini-strambi L. The risk of neurodegeneration in REM sleep behavior disorder : A systematic review and meta-analysis of longitudinal studies. *Sleep Med Rev.* 2019;43:37–46. doi: 10.1016/j.smrv.2018.09.008
13. Schenck CH. Update on Rapid-Eye-Movement Sleep Behavior Disorder (RBD): Focus on Its Strong

- Association with  $\alpha$ -Synucleinopathies. *Clin Transl Neurosci.* 2023;7:19. doi:10.3390/ctn7030019
14. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81 % of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder : a 16-year update on a previously reported series. *Sleep Med.* 2013;14:744–8. doi: 10.1016/j.sleep.2012.10.009
  15. Thangaleela S, Sivamaruthi BS, Kesika P. Neurological Insights into Sleep Disorders in Parkinson ' s Disease. *Brain Sci.* 2023;13. doi: 10.3390/ brainsci13081202
  16. Jiang Y, Chen Y, Li D, Zhu S, Gu R, Wang Y, et al. Sleep structure and related clinical characteristics in drug-naïve Parkinson's disease with subjectively different sleep quality. *Front Neurol.* 2023;14. doi:10.3389/fneur.2023.1156910
  17. Zhang Y, Ren R, Sanford LD, Yang L, Zhou J, Tan L, et al. Sleep in Parkinson's disease: A systematic review and meta-analysis of polysomnographic findings. *Sleep Med Rev.* 2020;51:101281. doi: 10.1016/j.smrv.2020.101281
  18. Cai GE, Luo S, Chen LN, Lu JP, Huang YJ, Ye QY. Sleep fragmentation as an important clinical characteristic of sleep disorders in Parkinson's disease: A preliminary study. *Chin Med J (Engl).* 2019;132:1788–95. doi: 10.1097/CM9.0000000000000329
  19. Jørgensen JT, Schernhammer E, Papantoniou K, Hansen J, Westendorp RGJ, Stayner L, et al. Night work and incidence of Parkinson's disease in the Danish Nurse Cohort. *Occup Environ Med.* 2021;78:419–25. doi: 10.1136/oemed-2020-107067
  20. Schernhammer ES, Lassen CF, Kenborg L, Ritz B, Olsen JH, Hansen J. Occupational history of night shift work and Parkinson's disease in Denmark. *Scand J Work Environ Health.* 2015;41:377–83. doi: 10.5271/sjweh.3502
  21. Wang ZZ, Sun Z, Zhang ML, Xiong K, Zhou F. Relationship between shift work, night work, and subsequent dementia: A systematic evaluation and meta-analysis. *Front Neurol.* 2022;13. doi: 10.3389/fneur.2022.997181
  22. Jin Y, Hur T, Hong Y. Circadian Rhythm Disruption and Subsequent Neurological Disorders in Night-Shift Workers. *J Lifestyle Med.* 2017;7:45–50. doi: 10.15280/jlm.2017.7.2.45
  23. Wang XL, Li L. Circadian Clock Regulates Inflammation and the Development of Neurodegeneration. *Front Cell Infect Microbiol.* 2021;11:1–16. doi: 10.3389/fcimb.2021.696554
  24. Fifel K, Videnovic A. Chronotherapies for Parkinson's disease. *Prog Neurobiol.* 2019;174:16–27. doi: 10.1016/j.pneurobio.2019.01.002
  25. Asadpoordezaki Z, Coogan AN, Henley BM. Chronobiology of Parkinson's disease: Past, present and future. *Eur J Neurosci.* 2023;57:178–200. doi: 10.1111/ejn.15859
  26. Yi Q, Yu-Peng C, Jiang-Ting L, Jing-Yi L, Qi-Xiong Q, Dan-Lei W, et al. Worse Sleep Quality Aggravates the Motor and Non-Motor Symptoms in Parkinson's Disease. *Front Aging Neurosci.* 2022;14:1–10. doi: 10.3389/fnagi.2022.887094
  27. Mizrahi-Kliger AD, Feldmann LK, Kühn AA, Bergman H. doi: *Exp Neurol.* 2022;350:113976. doi:

10.1016/j.expneurol.2022.113976

28. Zhu K, van Hilten JJ, Marinus J. The course of insomnia in Parkinson's disease. *Park Relat Disord.* 2016;33:51–7. doi: 10.1016/j.parkreldis.2016.09.010
29. Falup-pecurariu C, Diaconiu Ștefania. Personalized Assessment of Insomnia and Sleep Quality in Patients with Parkinson's Disease. *J Pers Med.* 2022;12. doi: 10.3390/jpm12020322
30. Piao Y, Lian T, Hu Y, Zuo L, Guo P, Yu S, et al. Restless legs syndrome in Parkinson disease : Clinical characteristics , abnormal iron metabolism and altered neurotransmitters. *Sci Rep.* 2017;1–10. doi:: 10.1038/s41598-017-10593-7
31. Ferini-strambi L, Carli G, Casoni F, Galbiati A. Restless Legs Syndrome and Parkinson Disease : A Causal Relationship Between the Two Disorders ? *Front Neurol.* 2018;9:1–12. doi: 10.3389/fneur.2018.00551
32. Fereshtehnejad SM, Yao C, Pelletier A, Montplaisir JY, Gagnon JF, Postuma RB. Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: A prospective study. *Brain.* 2019;142:2051–67. doi::10.1093/brain/awz111
33. Xu Z, Anderson KN, Pavese N. Longitudinal Studies of Sleep Disturbances in Parkinson's Disease. *Curr Neurol Neurosci Rep.* 2022;22:635–55. doi: 10.1007/s11910-022-01223-5
34. Mao J, Huang X, Yu J, Chen L, Huang Y. Association Between REM Sleep Behavior Disorder and Cognitive Dysfunctions in Parkinson's Disease : A Systematic Review and Meta-Analysis of Observational Studies. *Front Neurol.* 2020;11. doi: 10.3389/fneur.2020.577874
35. Li S, Lin Q, Bao Y, Feng Y, Li D, Zhang C. Impaired night-time mobility in patients with Parkinson's disease: a systematic review. *Front Aging Neurosci.* 2023;15. doi: 10.3389/fnagi.2023.1264143
36. Nagy A V., Leschziner G, Eriksson SH, Lees A, Noyce AJ, Schrag A. Cognitive impairment in REM-sleep behaviour disorder and individuals at risk of Parkinson's disease. *Park Relat Disord.* 2023;109:105312. doi: 10.1016/j.parkreldis.2023.105312
37. Shafazand S, Wallace DM, Arheart KL, Vargas S, Luca CC, Moore H, et al. Insomnia , Sleep Quality , and Quality of Life in Mild to Moderate Parkinson's Disease. *Ann Am Thorac Soc.* 2017;14. doi: 10.1513/AnnalsATS.201608-625OC

**TABLES**

**Table 1. Cohort characteristics**

<i>Cohort characteristics</i>	<i>PD sample (n=37)</i>	<i>Control sample (n=49)</i>	<i>Global cohort (n=86)</i>
<i>Age (years) (mean, ±SD)</i>	59.97, ±8.50	61.33, ±15.28	60.74, ±12.73
<i>Gender</i>			
<i>Males</i>	40.5% (n = 15)	44.9% (n = 22)	43% (n = 37)
<i>Females</i>	59.5% (n = 22)	55.1% (n = 27)	57% (n = 49)
<i>Sleep quality</i>			
<i>Global PSQI (mean, ±SD)</i>	6.757, ±4.212	8.143, ±3.403	7.546, ± 3.812
<i>PD stage</i>			
<i>Hoehn &amp; Yahr (mean, ±SD)</i>	2.071, ± 0.423	-	-
<i>MDS-UPDRS III (mean, ±SD)</i>	15,60, ± 9.876	-	-
<i>LEDD (mean, ±SD)</i>	641.946, ±327.918	-	-

PSQI, Pittsburgh Sleep Quality Index; LEDD, levodopa equivalent dose; MDS-UPDRS III, Movement Disorder Society – Unified Parkinson’s Disease Rating Scale; SD, Standard Deviation.

**Table 2. Correlations between sleep quality parameters and symptoms of Parkinson’s disease**

<i>Pearson correlations (r<sub>p</sub>)</i>	<i>PSQII</i>	<i>PSQI</i>	<i>PSQI3</i>	<i>PSQI4</i>	<i>PSQI5</i>	<i>PSQI6</i>	<i>PSQI7</i>	<i>Total PSQI</i>
<i>Hoehn &amp; Yahr</i>	<b>0.382</b> p=0.024	0.292 p=0.08	<b>0.334</b> p=0.05	<b>0.502</b> p=0.00	0.241 p=0.16	0.128 p=0.46	0.281 p=0.10	<b>0.443</b> p=0.00
<i>LEDD</i>	0.161 p=0.340	0.081 p=0.63	0.162 p=0.33	<b>0.295</b> p=0.07	0.252 p=0.13	-0.058 p=0.73	0.100 p=0.55	0.156 p=0.35
<i>Motor symptoms</i>								
<i>UPDRS I</i>	0.279 p=0.094	<b>0.410</b> p=0.01	-0.049 p=0.775	0.178 p=0.29	<b>0.412</b> p=0.01	0.180 p=0.28	0.249 p=0.28	0.284 p=0.08
<i>UPDRS II</i>	0.276 p=0.099	<b>0.280</b> p=0.09	0.087 p=0.61	0.087 p=0.90	<b>0.556</b> p<0.00	0.139 p=0.41	0.241 p=0.15	0.260 p=0.12

<i>UPDRS III</i>	<b>0.384</b> p=0.023 2	0.123 p=0.48 2	<b>0.428</b> p=0.01 0	<b>0.395</b> p=0.01 9	0.274 p=0.11 2	-0.030 p=0.86 2	0.134 p=0.44 2	<b>0.369</b> p=0.02 9
<i>UPDRS IV</i>	<b>0.403</b> p=0.013 0	0.198 p=0.24 0	0.286 p=0.08 6	<b>0.426</b> p=0.00 9	<b>0.378</b> p=0.02 1	0.187 p=0.26 8	0.222 p=0.18 7	<b>0.412</b> p=0.01 1
<b>Non-motor symptoms</b>								
<i>NMSS</i>	0.255 p=0.140 1	<b>0.518</b> p=0.00 1	0.061 p=0.72 6	-0.025 p=0.888 48	<b>0.339</b> p=0.04 7	0.059 p=0.73 5	0.182 p=0.29 5	0.234 p=0.17 6
<i>SCOPA – PS</i>	0.236 p=0.16 0	<b>0.443</b> p=0.006 1	0.102 p=0.54 7	0.124 p=0.46 4	<b>0.462</b> p=0.00 4	0.015 p=0.92 8	0.113 p=0.50 7	0.244 p=0.146 2
<i>MoCA</i>	-0.151 p=0.37 3	-0.130 p=0.442 3	-0.100 p=0.55 5	-0.180 p=0.28 5	0.312 p=0.06 0	-0.115 p=0.49 8	-0.035 p=0.83 5	-0.160 p=0.344 5
<i>BDI</i>	0.114 p=0.50 0	0.250 p=0.136 0	-0.028 p=0.86 9	-0.125 p=0.36 6	<b>0.537</b> p=0.00 1	-0.132 p=0.43 7	0.290 p=0.08 2	0.088 p=0.606 2
<i>PDQ – 39</i>	0.207 p=0.22 5	0.298 p=0.077 7	0.168 p=0.32 7	0.097 p=0.57 5	<b>0.423</b> p=0.01 0	-0.045 p=0.79 6	0.249 p=0.14 4	0.287 p=0.089 4

*PSQI*, Pittsburgh Sleep Quality Index; *LEDD*, LevoDopa Equivalent Dose; *MDS-UPDRS I-IV*, Movement Disorder Society – Unified Parkinson’s Disease Rating Scale; *MoCA*, Montreal Cognitive Assessment; *SCOPA-PS*, Scales for Outcomes in Parkinson’s Disease – Psychosocial Functioning; *PDQ-39*, Parkinson’s Disease Questionnaire; *NMSS*, Non-motor Symptom Scale; *BDI*, Beck Depression Index. *PSQI*, Pittsburgh Sleep Quality Index; *PSQII*, Subjective sleep quality; *PSQI2*, Sleep Latency; *PSQI3*, Sleep duration; *PSQI4*, Sleep efficiency; *PSQI5*, Sleep disturbances; *PSQI6*, Usage of sleep medication; *PSQI7*, Daytime dysfunction.

**Table 3. Sleep dysfunctions in Parkinson's disease vs. control subjects**

Subgroups based on their answers („yes” or „no”)	Parkinson's disease subjects		Control subjects	
	Yes	No	Yes	No
<b>Usage of sleep medication</b>	24.3%	75.7%	63.3%	36.7%
$\chi^2 = 12.850, df=1, p<0.001$	(n=9)	(n=28)	(n=31)	(n=18)
<b>History of work in night shift</b>	13.5%	86.5%	36.7%	63.3%(n=3)
$\chi^2 = 5.802, df=1, p=0.016$	(n=5)	(n=32)	(n=18)	1)
<b>Presence of sleep dysfunctions:</b>				
<b>Subjective sleep quality</b>	18.9%	81.1%	8.2% (n=4)	91.8%
$\chi^2 = 2.186, df=1, p=0.139$	(n=7)	(n=30)		(n=45)
<b>Sleep efficiency</b>	13.5%	86.5%	4.1% (n=2)	95.9%
$\chi^2 = 2.508, df=1, p=0.113$	(n=5)	(n=32)		(n=47)
<b>Diurnal functionality</b>	27.0%	73.0%	12.2%	87.8%(n=4)
$\chi^2 = 3.042, df=1, p=0.081$	(n=10)	(n=27)	(n=6)	3)
<b>Troubles initiating sleep</b>	43.2%	56.8%	73.5%	26.5%
$\chi^2 = 8.057, df=1, p=0.005$	(n=16)	(n=21)	(n=36)	(n=13)
<b>Nocturnal awakenings</b>	81.1%	18.9%	93.9%	6.1% (n=3)
$\chi^2 = 3.359, df=1, p=0.067$	(n=30)	(n=7)	(n=46)	
<b>Disordered breathing in sleep</b>	62.2%	37.8%	46.9%	53.1%
$\chi^2 = 1.964, df=1, p=0.161$	(n=23)	(n=14)	(n=23)	(n=26)
<b>Nightmares</b>	37.8%	62.2% (23)	55.1%	44.9%
$\chi^2 = 2.519, df=1, p=0.112$	(n=14)		(n=27)	(n=22)

**Table 4. Sleep quality in Parkinson's disease vs. control subjects**

Characteristics	PD sample		Control sample	
	Good sleep quality	Bad sleep quality	Good sleep quality	Bad sleep quality



Subgroups based on PSQI global score	<sup>27</sup> PSQI ≤ 5			Global PSQI	<sup>27</sup> PSQI > 5			Global PSQI
	(n = 17)	(n = 20)			(n = 13)	(n = 36)		
<b>Sleep components</b>								
<b>PSQI1</b>	0.588, ±0.507	1.500, ±0.688	<i>p</i> <0.001	<b>1.081, ±0.759</b>	0.750, ±0.622	1.486, ±0.562	<i>p</i> =0.002	<b>1.298, ±0.657</b> <0.001
<b>PSQI2</b>	0.294, ±0.470	1.600, ±1.231	<i>p</i> <0.001	<b>1.000, ±1.155</b>	0.850, ±0.801	1.810, ±0.668	<i>p</i> =0.001	<b>1.551, ±0.818</b> <0.001
<b>PSQI3</b>	0.294, ±0.470	1.600, ±1.231	<i>p</i> <0.001	<b>0.946, ±0.970</b>	0.167, ±0.389	0.639, ±0.798	<i>p</i> =0.010	<b>0.521, ±0.743</b> =0.001
<b>PSQI4</b>	0.118, ±0.332	1.500, ±1.051	<i>p</i> <0.001	<b>0.865, ±1.058</b>	0.333, ±0.492	1.139, ±0.990	<i>p</i> =0.001	<b>0.938, ±0.954</b> <0.001
<b>PSQI5</b>	1.118, ±0.600	1.550, ±0.510	<i>p</i> =0.026	<b>1.351, ±0.588</b>	0.923, ±0.494	1.556, ±0.504	<i>p</i> =0.001	<b>1.388, ±0.571</b> =0.010
<b>PSQI6</b>	0.294, ±0.772	0.700, ±1.261	<i>p</i> =0.239	<b>0.513, ±1.070</b>	0.333, ±0.651	1.778, ±0.989	<i>p</i> <0.001	<b>1.417, ±1.108</b> =0.001
<b>PSQI7</b>	0.588, ±0.507	0.950, ±1.050	<i>p</i> =0.183	<b>0.784, ±0.854</b>	0.833, ±0.577	1.222, ±0.591	<i>p</i> =0.059	<b>1.125, ±0.606</b> =0.015
<b>Total PSQI</b>	3.235, ±1.091	9.750, ±3.477	<i>p</i> <0.001	<b>6.757, ±4.212</b>	4.000, ±0.155	9.639, ±2.598	<i>p</i> <0.001	<b>8.143, ±3.403</b> <0.001
<b>Sleep duration (hours)</b>	6.985, ±0.731	5.750, ±1.209	<i>p</i> =0.001	<b>6.318, ±1.182</b>	7.125, ±0.678	8.563, ±11.467	<i>p</i> =0.459	<b>9.921, ±1.432</b> =0.623
<b>Sleep latency (minutes)</b>	19.352, ±41.845	46.275, ±51.936	<i>p</i> =0.090	<b>33.905, ±48.85</b>	17.846, ±9.371	40.139, ±37.081	<i>p</i> =0.002	<b>34.225, ±33.51</b> =0.056
				5				8

4

PSQI, Pittsburgh Sleep Quality Index; PSQ1, Subjective Sleep Quality Index; PSQI2, Sleep Latency; PSQI3, Sleep duration; PSQI4, Sleep efficiency; PSQI5, Sleep disturbances; PSQI6, Usage of sleep medication; PSQI7, Daytime dysfunction.

8

**Table 5. Variations in symptoms in Parkinson's disease in good or altered sleep quality**

Characteristics	PD Sample		
	PSQI ≤ 5 (n=17)	PSQI > 5 (n=20)	
<b>PSQI score</b>			
<b>Demographic characteristics</b>			
Age	59.71, ±8.153	60.20 ±8.983	<i>p</i> =0.862
Hoeh & Yahr score	1.882, ±0.332	2.250, ±0.429	<i>p</i> =0.008
LEDD	672.059, ±344.750	616.35, ±319.616	<i>p</i> =0.616
<b>Motor symptoms</b>			
MDS-UPDRS I	7.35, ±4.987	10.25, ±5.505	<i>p</i> =0.102
MDS-UPDRS II	9.24, ±8.664	11.50, ±7.273	<i>p</i> =0.400
MDS-UPDRS III	32.76, ±13.890	39.72, ±8.917	<i>p</i> =0.091
MDS-UPDRS IV	1.24, ±2.948	2.35, ±4.356	<i>p</i> =0.363
<b>Non-motor symptoms</b>			
MoCA	23.41, ±2.785	23.20, ±2.093	<i>p</i> =0.798
SCOPA-PS	6.00, ±5.136	10.10, ±7.166	<i>p</i> =0.051
PDQ-39	47.82, ±28.712	59.68, ±20.745	<i>p</i> =0.170
BDI	11.76, ±9.477	12.05, ±9.473	<i>p</i> =0.928
NMSS	43.88, ±32.482	51.89, ±41.565	<i>p</i> =0.529

16

PSQI, Pittsburgh Sleep Quality Index; BMI, Body Mass Index; LEDD, LevoDopa Equivalent Dose; MDS-UPDRS I- IV, Movement Disorder Society – Unified Parkinson's Disease Rating Scale; MoCA, Montreal Cognitive Assessment; SCOPA-PS, Scales for Outcomes in Parkinson's Disease – Psychosocial Functioning; PDQ-39, Parkinson's Disease Questionnaire; NMSS, Non-motor Symptom Scale; BDI, Beck Depression Index.

37